Stocks · Health care · Biological Products, (No Diagnostic Substances)

EXELIXIS, INC.

EXEL Clue Score84

United States Fiscal year ends January CIK 0000939767 Results filed 29 Oct 2026

Add to watchlist

What the insiders did Net selling

By person

17 insiders · 34 transactions

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

Dana Aftab

EVP, Research and Development

—

$7.70M (4)

−$7.70M

594,741

0.2400%

$31.91M

+18.9%

Patrick J. Haley

EVP, Commercial

—

$7.60M (7)

−$7.60M

357,638

0.1443%

$19.19M

−6.0%

Julie Smith

Director

—

$4.69M (3) scheduled

−$4.69M

28,957

0.0117%

$1.55M

+168.7%

Jack L Wyszomierski

Director

—

$4.58M (2) scheduled

−$4.58M

284,384

0.1148%

$15.26M

−18.6%

Christopher J. Senner

EVP and CFO

—

$4.56M (3)

−$4.56M

952,317

0.3843%

$51.10M

+32.0%

Stelios Papadopoulos

Director

—

$4.36M (1)

−$4.36M

1,197,595

0.4833%

$64.26M

−6.4%

George Poste

Director

—

$2.74M (1)

−$2.74M

127,199

0.0513%

$6.83M

−24.7%

Mary C Beckerle

Director

—

$1.93M (4) scheduled

−$1.93M

16,079

0.0065%

$862.80K

−53.1%

Bob Oliver

Director

—

$1.33M (2) scheduled

−$1.33M

29,487

0.0119%

$1.58M

−20.3%

David Edward Johnson

Director

$1.19M (1)

—

+$1.19M

1,553,262

0.6269%

$83.35M

+1.8%

Brenda Hefti

SVP and General Counsel

—

$1.15M (2) scheduled

−$1.15M

106,762

0.0431%

$5.73M

+17.8%

Maria C Freire

Director

—

$949.16K (1) scheduled

−$949.16K

109,186

0.0441%

$5.86M

+20.0%

Sue Gail Eckhardt

Director

—

$660.83K (2) scheduled

−$660.83K

16,079

0.0065%

$862.80K

−53.1%

Michael Morrissey

President and CEO

—

—

—

3,366,335

1.36%

$180.64M

+41.9%

Jeffrey Hessekiel

EVP & General Counsel

—

—

—

693,396

0.2798%

$37.21M

+30.6%

Amy C. Peterson

EVP Prod Dev & Med Aff & CMO

—

—

—

465,393

0.1878%

$24.97M

+44.5%

Tomas J. Heyman

Director

—

—

—

50,649

0.0204%

$2.72M

+36.8%